Medical Therapy: The Foundation

DHT-Blocking Therapy

The cornerstone of medical treatment for androgenetic alopecia is blocking DHT — the hormone driving follicular miniaturization. Two medications accomplish this: finasteride and dutasteride. Both inhibit 5-alpha reductase, the enzyme that converts testosterone to DHT, but they differ in scope. Finasteride (1 mg) blocks only the Type II isoform, reducing DHT by approximately 70%. Dutasteride (0.5 mg) blocks both Type I and Type II, reducing DHT by approximately 90%. Head-to-head studies consistently show that dutasteride is more effective.

The choice between them depends on where you are in life. For men in their twenties and thirties who have not yet finished having children, we tend to start with finasteride. It has a short half-life (6–8 hours, cleared in 1–2 days) and does not decrease sperm counts at the standard 1 mg dose. Dutasteride has a half-life of approximately 5 weeks and may slightly lower sperm counts, making it less ideal for men still planning a family. Once a man is done having children, we often transition to oral dutasteride for more comprehensive DHT suppression.

For younger men seeking more aggressive treatment without the systemic profile of oral dutasteride, there is an effective middle ground: topical dutasteride applied to the scalp, combined with oral finasteride. This delivers more potent DHT suppression at the follicular level while keeping systemic exposure lower than oral dutasteride alone.

Sexual side effects — decreased libido, erectile dysfunction — occur in approximately 2% of men taking oral finasteride and approximately 4% with oral dutasteride. These are reversible with discontinuation in the vast majority of cases. For patients who want to avoid any systemic sexual side-effect risk entirely, topical clascoterone blocks DHT at the follicle without reducing circulating hormone levels.

Oral Minoxidil

Low-dose oral minoxidil (typically 2.5–5 mg daily for men) complements DHT-blocking therapy by working through a different mechanism. Minoxidil prolongs the anagen (growth) phase and enhances blood flow and nutrient delivery to the follicle via vasodilation and direct stimulation of dermal papilla cells. It was originally a blood pressure medication, and at the low doses used for hair loss, it rarely has clinically significant effects on blood pressure.

Oral minoxidil is more effective than topical formulations — studies comparing twice-daily topical to once-daily oral show higher hair counts with the oral form — and most patients find it far more convenient. The most common side effect is hypertrichosis (increased body and facial hair), which is dose-dependent and reversible. Minoxidil is not associated with sexual side effects.

Custom Compounding

At HMI, we frequently use custom compounding to simplify treatment regimens. This includes both oral and topical formulations. A single all-in-one oral capsule combining minoxidil with dutasteride (or finasteride) can reduce daily pill burden to one medication. On the topical side, compounded solutions can deliver higher-concentration minoxidil (5–8%) combined with finasteride or dutasteride directly to the scalp, reducing systemic exposure while providing meaningful DHT reduction at the follicular level.

Regenerative Therapy: Augmenting the Foundation

Medical therapy is the foundation, but regenerative interventions can enhance and accelerate results. At HMI, the baseline regenerative protocol uses a fractional non-ablative laser (Lumenis M22 ResurFX at 1565nm—the same wavelength as the FDA-cleared Folix system) to stimulate angiogenesis and create microchannels in the scalp, followed by ultrasound-enhanced delivery of the Xtressé FR peptide concentrate. For patients who want to be more aggressive, microneedling with Xvie exosomes or injectable PRP can be added. At home, the Revian Red LLLT cap (10 minutes daily, with physician-monitored compliance) provides an additional layer of daily follicular stimulation.

These treatments complement, but do not replace, consistent medical therapy. Patients who expect regenerative treatments to work as a standalone solution are generally disappointed; those who use them to augment a solid medication regimen see measurably better outcomes.